SoundCell receives investment from UNIIQ and Delft Enterprises to identify antibiotic resistance faster


Proof-of-concept fund UNIIQ is investing 350,000 euros in Delft startup SoundCell together with DE (Delft Enterprises). The TU Delft spin-off is developing innovative technology that can measure the vibrations made by living bacteria. SoundCell’s technology has major implications for the detection and prevention of antibiotic resistance.

Aleksandre Japaridze and Irek Roslon, SoundCell

SoundCell will use the investment to develop a prototype of its device that can be used and tested in a hospital and to conduct additional clinical research.

Vibration as an indication

To accurately measure the vibrations of a single bacterium, SoundCell uses membranes made of graphene – a material consisting of a single layer of carbon atoms arranged in a pattern that visually resembles a honeycomb. By exploiting the extremely sensitive properties of graphene and the biological processes in bacteria, SoundCell provides insight into whether a bacterium is still alive (vibrating) after administration of an antibiotic. Initial experiments with E. Coli bacteria were clear: if the bacteria were resistant to the antibiotic, the vibrations remained at the same level. If the bacteria were not resistant, the vibrations decreased after administration of the drug.

“To understand how small these vibrations are, you can say that they are at least ten thousand times smaller than the thickness of a hair”

– SoundCell

The full article can be read on the InnovationQuarter website


  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…

  • VarmX recognised with two prestigious industry award nominations

    Leiden-based biotech company VarmX has received two industry award nominations recognising its scientific approach and strategic partnership with CSL. VarmX has been shortlisted for the 2026 Prix Galien USA “Best Startup” Award, which recognises early-stage companies developing novel therapeutic approaches.…